Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Philip J. Barter, et al. Circulation 2011;124:

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

1 Cardiovascular Disease in Asia. WHO CVD Atlas WHO Stroke Atlas The Burden of CVD in Asia: Stroke Deaths by Country,

Kastelein JJ, et al. Circulation 2008;117: On-Treatment Values of Lipids, Apolipoproteins, and Their Ratios in Both Treatment Groups of TNT and IDEAL.

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Physician and Patient Influences on Provider Performance

Circ Cardiovasc Qual Outcomes

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Effect of Provider Volume on the Accuracy of Hospital Report Cards

Circ Cardiovasc Imaging

Iatrogenic Adverse Events in the Coronary Care Unit

by Johan Denollet, Angélique A. Schiffer, and Viola Spek

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Circ Cardiovasc Qual Outcomes

Risk of Heart Failure Among Postmenopausal WomenCLINICAL PERSPECTIVE

Mathematical representation of Bayes theorem.

Circ Cardiovasc Qual Outcomes

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

Circ Cardiovasc Interv

Using the Coronary Artery Calcium Score to Guide Statin Therapy

Circ Cardiovasc Interv

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Association between highest tertile for homocysteine and mortality

A: Kaplan-Meier estimate of time to first LLA

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction Victoria Hamill, PhD, Ian Ford, PhD, Kim Fox, MD,

Eric Peterson Journal of Indian College of Cardiology

Fung TT, et al. Circulation 2009;119:

Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Life expectancy and baseline BP: Male participants

Risk for BMI outcome (%)

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Enrollment and Outcomes

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Baseline Characteristics According to Sex

Pamela E. Scott et al. JACC 2018;71:

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

The ACCORD Study Group. NEJM 2010; Epub March 14

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

HRs for prostate cancer by medication status.

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Christian Madelaire et al. JCHF 2018;6:

Frankel DS, et al. J Am Coll Cardiol. 2009;53:754-62

Increase of physical activity over time associated with lower HF risk

Expert Perspectives.

Subgroup analysis of associations between egg consumption and risk of incident cardiovascular disease (CVD), ischaemic heart disease (IHD), haemorrhagic.

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Cost-effectiveness acceptability frontier for three risk-assessment strategies related to pressure-injury prevention best practices from a US societal.

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Presentation transcript:

Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Baseline Differences for Women With CVD According to Aspirin Dose Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Clinical Outcomes According to Aspirin Use and Dose Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Adjusted Cox proportional hazards analyses of time to adverse outcomes among women with CVD (n=8928) Jeffrey S. Berger, et al. Circ Card Qual Out 2009;2:78-87

Subgroup analyses according to aspirin use Jeffrey S. Berger, et al. Circ Card Qual Out 2009;2:78-87

Clinical outcomes according to aspirin use Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Clinical outcomes according to aspirin dose Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Clinical Perspective Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87